Winters Loren, Habin Karleen, Flanagan Jane, Cashavelly Barbara J
Gillette Center for Breast Cancer, Massachusetts General Hospital, Boston, USA.
Clin J Oncol Nurs. 2010 Jun;14(3):379-82. doi: 10.1188/10.CJON.379-382.
Aromatase inhibitors (AIs) are recommended for the treatment of estrogen-sensitive breast cancer in postmenopausal women and provide a superior risk reduction compared to five years of tamoxifen alone. Arthralgias, a common side effect of AIs, may adversely affect quality of life, treatment adherence, and persistence. Early discontinuation of AIs may result in an inadequate clinical response. Over-the-counter analgesics, exercise, and drug holidays are common strategies used to manage arthralgias, however few interventions are evidence-based. Patients experiencing arthralgias may experience distress and, therefore would benefit from ongoing nursing support. When caring for patients with arthralgias, nurses should assess for potential modifiable risk factors, recommend lifestyle changes and/or pharmacologic interventions, and offer ongoing education and follow-up.
芳香化酶抑制剂（AIs）被推荐用于治疗绝经后女性的雌激素敏感性乳腺癌，与单独使用五年他莫昔芬相比，能更有效地降低风险。关节痛是AIs的常见副作用，可能对生活质量、治疗依从性和持续性产生不利影响。过早停用AIs可能导致临床反应不足。非处方镇痛药、运动和药物假期是常用的管理关节痛的策略，但很少有干预措施是基于证据的。经历关节痛的患者可能会感到痛苦，因此持续的护理支持会对他们有益。在护理有关节痛的患者时，护士应评估潜在的可改变风险因素，推荐生活方式改变和/或药物干预措施，并提供持续的教育和随访。
